Arsenic-Containing Qinghuang Powder(青黄散)Is An Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy  

作　　者：FAN Teng QUAN Ri-cheng LIU Wei-yi XIAO Hai-yan TANG Xu-dong LIU Chi LI Liu LV Yan WANG Hong-zhi XU Yong-gang GUO Xiao-qing HU Xiao-mei 

机构地区：[1]Department of Hematology,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijin g(100091),China [2]Graduate School,China Academy of Chinese Medical Sciences,Beijing(100700),China

出　　处：《Chinese Journal of Integrative Medicine》2020年第5期339-344,共6页中国结合医学杂志（英文版）

基　　金：Supported by Special Grants of Clinical Research Base of Traditional Chinese Medicine,State Administration of Traditional Chinese Medicine(No.JDZX2012180)。

摘　　要：Objective:To analyze the overall survival(OS)of elderly acute myeloid leukemia(AML)patients treated with oral arsenic-containing Qinghuang Powder(青黄散,QHP)or low-intensity chemotherapy(LIC).Methods:Forty-two elderly AML patients treated with intravenous or subcutaneous LIC(1 month for each course,at least 3 courses)or oral QHP(3 months for each course,at least 2 courses)were retrospectively analyzed from January 2015 to December 2017.The main endpoints of analysis were OS and 1-,2-,3-year OS rates of patients,respectively.And the adverse reactions induding bone marrow suppression,digestive tract discomfort and myocardia injury were observed.Results:Out of 42 elderly AML patients,22 received LIC treatment and 20 received QHP treatment,according to patients'preference.There was no significant difference on OS between LIC and QHP patients(13.0 months vs.13.5 months,P>0.05).There was no significant difference on OS rates between LIC and QHP groups at 1 year(59.1%vs.70.0%),2 years(13.6%vs.15%),and 3 years(4.6%vs.5.0%,all P>0.05).Furthermore,there was no significant difference of OS on prognosis stratification of performance status>2(12 months vs.12 months),age>75 year-old(12.0 months vs.12.5 months),hematopoietic stem cell transplant comorbidity index>2(12 months vs.13 months),poor cytogenetics(12 months vs.8 months),and diagnosis of secondary AML(10 months vs.14 months)between LIC and QHP patients(P>0.05).Conclusion:QHP may be an alternative treatment for elderly AML patients refusing LIC therapy.

关 键 词：acute MYELOID LEUKEMIA Qinghuang Powder REALGAR arsenic ELDERLY patient Chinese medicine 

分 类 号：R733.71[医药卫生—肿瘤]